Studies Addressing Rare Neurodegenerative Diseases including ALS
Food and Drug Administration
The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development.
Deadline
Not published. Check the funder's page.
Who can apply
Open to: Public and State controlled institutions of higher education; County governments; Native American tribal governments (Federally recognized); Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"; Native American tribal organizations (other than Federally recognized tribal governments); State governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments.
Sources
Grants.gov. Last updated 2026-10-26.
Always confirm eligibility and deadlines on the funder's own page before applying.